GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Forward Dividend Yield %

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Forward Dividend Yield % : 0.00% (As of May. 22, 2024)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Forward Dividend Yield %?

As of today (2024-05-22), the Forward Annual Dividend Yield of EOM Pharmaceutical Holdings is 0.00%.

As of today (2024-05-22), the Trailing Annual Dividend Yield of EOM Pharmaceutical Holdings is 0.00%.

IMUC's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.55
* Ranked among companies with meaningful Forward Dividend Yield % only.

EOM Pharmaceutical Holdings's Dividends per Share for the three months ended in Jun. 2018 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of EOM Pharmaceutical Holdings's Forward Dividend Yield %

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Forward Dividend Yield % falls into.



EOM Pharmaceutical Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


EOM Pharmaceutical Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077